EUVIMEDDescoperă EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective

Nicolò Bisi iD, Abdallah Hamze iD

Pharmaceuticals · 2026-07-24 · 19 (8) · 1146

DOI: 10.3390/ph19081146 ↗

At a glance

Übersichtsarbeit in Pharmaceuticals, published online on 2026-07-24. Written by Nicolò Bisi and 1 co-authors. Institution: Department of Chemistry, Université Paris-Saclay, CNRS, BioCIS, Bat. Henri Moissan, 17, Av. des Sciences, 91400 Orsay, France. Cited 1 times so far (Crossref); 113 references. The full text is freely available (open access, CC BY 4.0).

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Background/Objectives: Cancer resistance, pathway redundancy, and compensatory signaling challenge traditional therapies. Dual target strategies address this by engaging two disease-relevant proteins within a single molecule. This review compares classical dual inhibitors with dual proteolysis-targeting chimeras (dual PROTACs) to evaluate the therapeutic advantages of degradation over occupancy.

Methods

We examine oncology target pairs featuring documented examples of both dual inhibitors and dual PROTACs. The biological rationale for co-targeting is analyzed alongside a comparative assessment of their chemical frameworks, focusing heavily on the synthetic strategies, length, and structure of linkers required for dual PROTAC ternary complex formation.

Results

While dual inhibitors rely on active-site occupancy, dual PROTACs leverage the ubiquitin–proteasome system for catalytic target elimination. Transitioning from dual inhibition to dual degradation in most cases (>85%) enhances antitumor efficacy, extends duration of action, and overcomes resistance mutations. Optimizing linker design remains the critical factor in balancing the simultaneous degradation kinetics of two distinct proteins.

Conclusions

Dual PROTACs provide distinct advantages over traditional inhibitors by completely destroying target proteins rather than merely blocking them. This comparison offers a practical entry point and actionable synthetic strategies for medicinal chemists designing multi-target protein degraders.

Subjects

Author keywords

dual PROTACsdual inhibitorsoncologypolypharmacologytargeted protein degradation

Authors and institutions

  • Department of Chemistry, Université Paris-Saclay, CNRS, BioCIS, Bat. Henri Moissan, 17, Av. des Sciences, 91400 Orsay, France.

ORCID profiles: Nicolò Bisi, Abdallah Hamze

Cite

APA

Bisi, N., & Hamze, A. (2026). Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective. Pharmaceuticals, 19(8), 1146. https://doi.org/10.3390/ph19081146

Vancouver

Bisi N, Hamze A. Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective. Pharmaceuticals. 2026;19(8):1146. doi:10.3390/ph19081146

BibTeX
@article{Bisi2026,
  author = {Bisi, Nicolò and Hamze, Abdallah},
  title = {Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1146},
  doi = {10.3390/ph19081146}
}
Start for free →